Patents by Inventor Jens HUKELMANN

Jens HUKELMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF IDENTIFYING METASTATIC LESIONS IN A PATIENT AND TREATING THEREOF
    Publication number: 20230190805
    Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
    Type: Application
    Filed: October 5, 2022
    Publication date: June 22, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Jens FRITSCHE, Oliver SCHOOR, Frank SCHWOEBEL, Lena Katharina FREUDENMANN
  • TCR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING
    Publication number: 20230190807
    Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
    Type: Application
    Filed: October 5, 2022
    Publication date: June 22, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Jens FRITSCHE, Oliver SCHOOR, Frank SCHWOEBEL, Lena Katharina FREUDENMANN
  • METHODS OF TREATING METASTATIC LESIONS AND COMPOSITIONS THEREOF
    Publication number: 20230190806
    Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
    Type: Application
    Filed: October 5, 2022
    Publication date: June 22, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Jens FRITSCHE, Oliver SCHOOR, Frank SCHWOEBEL, Lena Katharina FREUDENMANN
  • INDICATIONS FOR ANTI-PRAME BINDERS
    Publication number: 20230190808
    Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
    Type: Application
    Filed: October 6, 2022
    Publication date: June 22, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Jens FRITSCHE, Oliver SCHOOR, Frank SCHWOEBEL, Lena Katharina FREUDENMANN
  • VACCINE COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230181729
    Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
    Type: Application
    Filed: October 6, 2022
    Publication date: June 15, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Jens FRITSCHE, Oliver SCHOOR, Frank SCHWOEBEL, Lena Katharina FREUDENMANN
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20220226376
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 21, 2022
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20220111022
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 29, 2021
    Publication date: April 14, 2022
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20220098269
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 29, 2021
    Publication date: March 31, 2022
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR